Explore 3 Stock Ideas & Industry Insights Download Free Report

Annexon Inc

Company price
3.41 USD -0.11 ( 3.12%)
Last update at 2026-11-19T21:00:00Z
VOLUME
3134028
Market Cap
994.94M

Momentum Score

…

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.40
Low
3.66
High
52 Week Price Range
1.60
Low
7.18
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Annexon Inc is a clinical-stage biopharmaceutical company developing therapies that inhibit the classical complement pathway to address neurodegenerative and autoimmune disorders. Long-term growth may be driven by clinical progress across its programs, expansion into additional neurological and immune indications, and partnerships that could extend its platform and appeal to investors seeking exposure to a novel mechanism addressing unmet needs.

Major risks include high dependency on early-stage clinical outcomes, significant regulatory and development uncertainty, no meaningful product revenue requiring additional financing, and competition from other complement and immunomodulatory approaches.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
3.52
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.12
ROE
-81.90%
Net Debt
-135.85M
ROCE
-92.11%
Diluted EPS TTM
-1.34

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -206.69M -138.20M -134.24M -141.95M -130.32M
Net income -206.69M -138.20M -134.24M -138.29M -127.79M
Selling general administrative 31.71M 34.62M 28.02M 33.10M 30.65M
Selling and marketing expenses - - 3.27M - -
Gross profit -3.69M -3.45M -3.27M - -
Reconciled depreciation 2.17M 2.15M 2.14M 2.11M 2.14M
Ebit -216.41M -138.20M -143.72M -147.71M -132.85M
Ebitda -213.76M -134.75M -141.57M -145.60M -130.71M
Depreciation and amortization 2.65M 3.45M 2.15M 2.11M 2.14M
Operating income -216.41M -154.07M -143.72M -145.60M -130.71M
Other operating expenses 216.41M 154.07M 143.72M 145.60M 130.71M
Interest expense - - - 3.65M 2.14M
Tax provision - - - - 0.00M
Interest income 9.72M 15.87M 9.68M 3.65M 0.39M
Net interest income 9.72M 15.87M 9.68M 3.65M 0.39M
Income tax expense - - - -3.65M -2.53M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 212.72M 150.62M 143.72M 145.60M 130.71M
Cost of revenue 3.69M 3.45M 3.27M - -
Total other income expense net 9.72M 15.87M 9.49M 3.65M 0.39M
Net income from continuing ops -206.69M -138.20M -140.73M -145.60M -130.71M
Net income applicable to common shares - - - -141.95M -130.32M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 277.57M 350.07M 297.67M 285.10M 287.04M
Other current assets 3.85M 4.44M 4.14M 5.44M 4.98M
Total liab 65.92M 56.97M 47.12M 53.90M 55.13M
Total stockholder equity 211.65M 293.11M 250.56M 231.19M 231.91M
Other current liab 24.79M 17.57M 10.28M 13.63M 0.14M
Common stock 0.15M 0.11M 0.08M 0.05M 0.04M
Capital stock 0.15M 0.11M 0.08M 0.05M 0.04M
Retained earnings -917.39M -710.70M -572.50M -438.26M -296.31M
Other assets - - 0.00M 1.03M 1.17M
Cash 162.05M 49.50M 225.11M 140.02M 74.84M
Total current liabilities 42.63M 30.51M 17.93M 22.36M 21.74M
Current deferred revenue - - - - 9.25M
Net debt -135.85M -20.53M -193.75M -107.16M -40.25M
Short term debt 2.91M 2.52M 2.17M 1.32M 1.20M
Short long term debt total 26.20M 28.97M 31.36M 32.86M 34.59M
Other stockholder equity 1128.92M 1003.68M 823.03M 669.78M 528.37M
Property plant equipment - - - 16.84M 38.18M
Total current assets 242.19M 316.46M 263.86M 248.10M 247.69M
Net tangible assets - - - 231.19M 231.91M
Short term investments 76.29M 262.52M 34.61M 102.64M 167.87M
Accounts payable 14.93M 10.43M 5.49M 7.42M 11.15M
Accumulated other comprehensive income -0.03M 0.01M -0.05M -0.37M -0.18M
Common stock total equity - - - 0.05M 0.04M
Retained earnings total equity - - - -438.26M -296.31M
Non currrent assets other 9.58M 4.27M 1.03M 1.03M 1.17M
Non current assets total 35.38M 33.61M 33.81M 37.00M 39.35M
Capital lease obligations 26.20M 28.97M 31.36M 32.86M 34.59M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 190.19M -218.80M 29.27M 64.97M -86.58M
Change to liabilities - - - 5.93M 3.86M
Total cashflows from investing activities 190.05M -218.80M 70.70M 58.44M -88.24M
Total cash from financing activities 108.86M 161.21M 135.52M 122.91M 1.79M
Change to operating activities - - - 4.03M -0.57M
Net income -206.69M -138.20M -134.24M -141.95M -130.32M
Change in cash 112.55M -175.61M 85.09M 65.04M -192.56M
Begin period cash flow 50.53M 226.14M 141.05M 76.01M 268.56M
End period cash flow 163.08M 50.53M 226.14M 141.05M 76.01M
Total cash from operating activities -186.36M -118.01M -121.14M -116.31M -106.11M
Issuance of capital stock 109.56M 161.87M 17.55M 130.48M 0.00M
Depreciation 2.17M 2.15M 2.15M 2.11M 2.14M
Dividends paid 1.86M - - - -
Sale purchase of stock - - - 121.40M 1.79M
Other cashflows from financing activities 0.24M -0.67M 0.01M -7.57M 1.79M
Change to netincome - - - 18.52M 18.79M
Capital expenditures 0.14M 0.01M 0.19M 6.53M 1.65M
Cash flows other operating - - - -0.99M -0.21M
Cash and cash equivalents changes - - - 65.04M -192.55M
Change in working capital 4.23M 6.36M -5.80M 3.74M 3.28M
Stock based compensation 16.42M 19.43M 18.18M 18.52M 16.26M
Other non cash items -2.48M -7.75M -1.43M 1.28M 1.27M
Free cash flow -186.49M -118.02M -121.33M -122.83M -107.76M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
ANNX
Annexon Inc
-0.11
3.12%
3.41 - - - 4.88 -2.47
NVO
Novo Nordisk A/S
-0.54
1.36%
38.90 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc
-
-%
520.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc
2.34
0.25%
923.34 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 36.06

Profile*

Annexon Inc

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

1400 Sierra Point Parkway, Brisbane, CA, United States, 94005

650 822 5500

96

Name Title Year Born
Mr. Douglas Love J.D., Esq. CEO, Pres & Director 1968
Dr. Larry C. Mattheakis Ph.D. Exec. VP & Chief Scientific Officer 1957
Dr. Ted Yednock Ph.D. Exec. VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board 1958
Dr. Arnon Rosenthal Ph.D. Founder 1956
Ms. Jennifer Lew Exec. VP & CFO 1973
Miriam Mason Sr. VP of Corp. Communications NA
Mr. Michael Overdorf M.B.A. Exec. VP & Chief Bus. Officer 1970
Henk-Andre Kroon M.D. Sr. VP of Translational Medicine NA
Mirella Villa Del Toro Sec. NA
Mr. Douglas Love Esq., J.D. CEO, President & Director 1968

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…